We recently identified a specific area in the TERT promoter, termed THOR (TERT Hypermethylated Oncological Region), which is hypermethylated only in cancers expressing TERT and non-hypermethylated in normal tissues and low-grade pediatric tumors, which do not express TERT. THOR predicted outcome and tumor progression in several subgroups of pediatric cancers [27]. The gene discussed is THORLNC; the disease is cancer.